Sort   by:  
 Page size 
UnknownNivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.
Not available
S-EPMC12702069 | biostudies-literature
UnknownReal-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Not available
S-EPMC10546827 | biostudies-literature
UnknownPaclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Not available
S-EPMC10622534 | biostudies-literature
Sort   by:  
 Page size